Specifically, glioma cells express endocannabinoid‐sensing GPCRs (i.e., type‐1 cannabinoid receptor, CB1R; and type‐2 cannabinoid receptor, CB2R), whose pharmacological activation targets multiple cancer hallmarks such as resistance to programmed cell death, angiogenesis, cell proliferation, and cell invasiveness and metastasis (Dumitru et al., 2018; Ellert‐Miklaszewska et al., 2020; Velasco et al., 2012). This evidence concerns the gene CNR1 and glioma.